Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Woodinville, Washington 98072


Purpose:

Diseases caused by brain energy supply defects can be innate (fibromyalgia secondary to familial mitochondrial disorders) or acquired (tardive dyskinesia or weight gain associated with prolonged antipsychotic use). Patients with these possible mitochondrial disorders will provide a baseline resting heart rate sample, ingest low-dose metformin (500 mg), and then provide an additional sample 2 hours later.


Study summary:

Doctors need to develop tests which inexpensively and reliably evaluates brain metabolism. Current diagnostic tests sample other tissues which often run on different fuels (fats), utilize unproven and often insensitive brain imaging scanners, or sequence thousands to millions of base-pairs of DNA. All of these tests are expensive. None of these tests accurately or completely capture the interactions between the 1000s of proteins involved in brain metabolism. The investigators suspect that mathematical analysis of the resting heart rate may provide some insight into brain metabolism. The brain controls heart rate in response to changes in blood pressure and blood gases like carbon dioxide and oxygen. Tight control of heart rate is necessary to make sure that the brain has the right mix of fuel and air. Because the brain can't respond instantly to changes in its fuel supply, this system acting as a biological carburetor has a natural oscillatory rhythm that can be monitored just like frequencies on the radio. The investigators propose to amplify these rhythms by modestly metabolically stressing the brain with metformin, a inhibitor of complex 1 in the mitochondria.


Criteria:

Inclusion Criteria: EITHER chronic neurogenic pain meeting ACR criteria for fibromyalgia or previous/current exposure to antipsychotic medications Exclusion Criteria: - recent infection, - renal failure, - pre-existing cardiac disease, - COPD, - inability to participate in informed consent, - lack of transport to return home from study site, - severe fasting intolerance or hypoglycemia, - history of stroke-alike episode, - uncontrolled migraine or cyclic vomiting, - diabetes on insulin or sulfonylurea, - non-English speaker, - medications with strong effects on baseline heart rate variability


NCT ID:

NCT02500628


Primary Contact:

Principal Investigator
Jon E Berner, MD PhD
Woodinville Psychiatric Associates


Backup Contact:

N/A


Location Contact:

Woodinville, Washington 98072
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.